![Promising Safety and Efficacy Signals from a Small Phase 1 Pilot Study (PRIMETIME) with RRx-001 + Opdivo® [nivolumab] in Traditionally Checkpoint Inhibitor Non-Responsive Tumors](https://www.epicentrx.com/wp-content/uploads/2021/10/default-980x653-1.jpg)
by EpicentRx | Mar 15, 2023 | 2023, Press Releases
The combination of RRx-001 + Opdivo was well tolerated PRIMETIME was a small, duration-limited pilot study with an encouraging but preliminary anticancer signal in cold, non-immunogenic tumors TORREY PINES, Calif., March 15, 2023 /PRNewswire/ — EpicentRx, a...
by EpicentRx | Mar 15, 2023 | Blog
The maxim that “a man’s home is his castle” is made literal by tumors, which firmly entrench themselves behind castle-like barriers as a defense against the attritional war waged against them by chemotherapy, radiation, and immunotherapy. These barriers are...
by EpicentRx | Mar 9, 2023 | Blog
On Sunday, March 12 at 2 a.m., don’t forget to advance your clocks forward one hour for Daylight Saving Time (DST). (Remember spring forward, fall back). This applies to most of the country, Hawaii, Arizona, Puerto Rico, Guam, and the U.S. Virgin Islands excepted....
by EpicentRx | Mar 8, 2023 | Blog
In a TV review about a serial killer, we came across this pithy phrase: “all killer, no filler” (AKNF). AKNF denotes no extraneous content i.e., no filler, which perfectly encapsulates the minimalist design and effectiveness of the oncolytic adenovirus, AdAPT-001....
by EpicentRx | Mar 2, 2023 | Blog
“Anergy” is a commonly used term in immuno-oncology, particularly in conjunction with T cells. So, what exactly does it mean and in what context is it used? The dictionary defines it as the “absence of the normal immune response to a particular antigen or allergen.” A...
